• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Neutrophil-to-Apolipoprotein A1 Ratio Predicted Overall Survival in Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.中性粒细胞与载脂蛋白A1比值可预测接受经动脉化疗栓塞术的肝细胞癌患者的总生存期。
Oncologist. 2021 Aug;26(8):e1434-e1444. doi: 10.1002/onco.13743. Epub 2021 Mar 24.
2
Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.炎症评分可预测接受经动脉化疗栓塞术和重组人5型腺病毒H101治疗的肝细胞癌患者的生存情况。
PLoS One. 2017 Mar 29;12(3):e0174769. doi: 10.1371/journal.pone.0174769. eCollection 2017.
3
Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.炎症评分可预测经动脉化疗栓塞术后乙型肝炎病毒相关肝细胞癌患者的生存情况。
World J Gastroenterol. 2015 May 14;21(18):5582-90. doi: 10.3748/wjg.v21.i18.5582.
4
Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.意大利肝癌项目评分有助于识别巴塞罗那临床肝癌C期患者中经动脉化疗栓塞术的潜在候选者。
Hepatobiliary Pancreat Dis Int. 2016 Apr;15(2):152-7. doi: 10.1016/s1499-3872(16)60070-x.
5
Prognostic Value of Serum Apolipoprotein B to Apolipoprotein A-I Ratio in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis.载脂蛋白 B 与载脂蛋白 A-I 比值对经导管动脉化疗栓塞治疗的肝细胞癌患者预后的预测价值:倾向评分匹配分析。
Oncol Res Treat. 2021;44(9):450-468. doi: 10.1159/000517735. Epub 2021 Aug 11.
6
A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.术前中性粒细胞与淋巴细胞比值和淋巴细胞与单核细胞比值的联合作为经动脉化疗栓塞巨大肝细胞癌后生存结局的有用预测指标。
Saudi Med J. 2020 Apr;41(4):376-382. doi: 10.15537/smj.2020.4.24911.
7
Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.六分和十二分标准在肝功能评分 1 级接受经动脉化疗栓塞治疗的肝细胞癌患者中的验证。
World J Gastroenterol. 2020 Apr 21;26(15):1805-1819. doi: 10.3748/wjg.v26.i15.1805.
8
A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.一种基于新 ALBI 模型预测巴塞罗那临床肝癌分期 B 期患者经肝动脉化疗栓塞治疗后的生存情况。
Liver Int. 2019 Sep;39(9):1704-1712. doi: 10.1111/liv.14194. Epub 2019 Jul 30.
9
Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.经动脉化疗栓塞联合重组人5型腺病毒H101可延长中晚期肝细胞癌患者的总生存期:一项预后列线图研究
Chin J Cancer. 2017 Jul 20;36(1):59. doi: 10.1186/s40880-017-0227-2.
10
Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.中期肝细胞癌:炎症评分在预测接受经动脉化疗栓塞治疗患者无进展生存期的价值比较。
J Cancer Res Ther. 2021 Jul;17(3):740-748. doi: 10.4103/jcrt.jcrt_29_21.

引用本文的文献

1
Blood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients.血脂代谢生物标志物正逐渐成为癌症患者生存的重要预后指标。
BMC Cancer. 2024 Dec 18;24(1):1549. doi: 10.1186/s12885-024-13265-8.
2
The neutrophil-to-apolipoprotein A1 ratio is associated with adverse outcomes in patients with acute decompensated heart failure at different glucose metabolic states: a retrospective cohort study.中性粒细胞与载脂蛋白 A1 比值与不同糖代谢状态急性失代偿性心力衰竭患者不良预后的相关性:一项回顾性队列研究。
Lipids Health Dis. 2024 Apr 22;23(1):118. doi: 10.1186/s12944-024-02104-1.
3
CD137 and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.CD137 和调节性 T 细胞作为一线免疫治疗治疗的晚期非成瘾性非小细胞肺癌患者生存的独立预后因素。
J Transl Med. 2024 Apr 3;22(1):329. doi: 10.1186/s12967-024-05142-6.
4
Predictive value of neutrophil to apolipoprotein A1 ratio in patients with acute ischaemic stroke.中性粒细胞与载脂蛋白A1比值对急性缺血性脑卒中患者的预测价值。
Brain Commun. 2024 Mar 21;6(2):fcae091. doi: 10.1093/braincomms/fcae091. eCollection 2024.
5
Erythroid-transdifferentiated myeloid cells promote portal vein tumor thrombus in hepatocellular carcinoma.红细胞向骨髓细胞分化促进肝癌门静脉癌栓形成。
Theranostics. 2023 Jul 31;13(13):4316-4332. doi: 10.7150/thno.82907. eCollection 2023.
6
Editorial: Myeloid-derived suppressor cells in inflammation and its complications and cancers.社论:炎症及其并发症和癌症中的髓源性抑制细胞
Front Immunol. 2023 Jul 18;14:1240415. doi: 10.3389/fimmu.2023.1240415. eCollection 2023.
7
Lipid metabolism and tumor immunotherapy.脂质代谢与肿瘤免疫治疗
Front Cell Dev Biol. 2023 May 16;11:1187989. doi: 10.3389/fcell.2023.1187989. eCollection 2023.
8
Predictive value of neutrophil-to-apolipoprotein A1 ratio in all-cause and cardiovascular death in elderly non-valvular atrial fibrillation patients.中性粒细胞与载脂蛋白A1比值对老年非瓣膜性心房颤动患者全因死亡和心血管死亡的预测价值
Heliyon. 2023 Jan 11;9(1):e12918. doi: 10.1016/j.heliyon.2023.e12918. eCollection 2023 Jan.
9
Apolipoproteins: New players in cancers.载脂蛋白:癌症中的新角色。
Front Pharmacol. 2022 Nov 25;13:1051280. doi: 10.3389/fphar.2022.1051280. eCollection 2022.
10
Association of the MACROD2 rs6110695 A>G polymorphism with an increasing WBC count in a Korean population.MACROD2 rs6110695 A>G 多态性与韩国人群白细胞计数增加的关联。
Immun Inflamm Dis. 2022 Jul;10(7):e669. doi: 10.1002/iid3.669.

本文引用的文献

1
Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies.肌肉减少症是接受经动脉化疗栓塞术(TACE)治疗肝恶性肿瘤患者的不良预后因素。
Cancers (Basel). 2019 Oct 8;11(10):1503. doi: 10.3390/cancers11101503.
2
Prognostic significance of lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation.淋巴细胞与单核细胞比值及血小板与淋巴细胞比值在接受经动脉化疗栓塞和射频消融的肝细胞癌患者中的预后意义
Onco Targets Ther. 2019 Sep 2;12:7129-7137. doi: 10.2147/OTT.S217935. eCollection 2019.
3
Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy.经动脉化疗栓塞(TACE)治疗后血小板相关预后模型对恶性肝肿瘤患者预后价值的比较
Acta Cir Bras. 2019 Sep 16;34(7):e201900710. doi: 10.1590/s0102-865020190070000010.
4
Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer.载脂蛋白A-I(ApoA-I)、免疫、炎症与癌症。
Cancers (Basel). 2019 Aug 1;11(8):1097. doi: 10.3390/cancers11081097.
5
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.乐伐替尼用于超出七项标准且肝功能为Child-Pugh A级的中期肝细胞癌患者的初始治疗:一项概念验证研究。
Cancers (Basel). 2019 Jul 31;11(8):1084. doi: 10.3390/cancers11081084.
6
Diagnostic and prognostic significance of mRNA expressions of apolipoprotein A and C family genes in hepatitis B virus-related hepatocellular carcinoma.载脂蛋白A和C家族基因mRNA表达在乙型肝炎病毒相关性肝细胞癌中的诊断和预后意义
J Cell Biochem. 2019 Oct;120(10):18246-18265. doi: 10.1002/jcb.29131. Epub 2019 Jun 18.
7
Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.靶向髓源性抑制细胞治疗肝细胞癌:现状与未来展望
J Hepatocell Carcinoma. 2019 May 7;6:71-84. doi: 10.2147/JHC.S159693. eCollection 2019.
8
Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis.受体相互作用蛋白激酶 3 缺陷通过趋化因子(C-X-C 基序)配体 1-趋化因子(C-X-C 基序)受体 2 轴招募髓源性抑制细胞进入肝细胞癌。
Hepatology. 2019 Nov;70(5):1564-1581. doi: 10.1002/hep.30676. Epub 2019 Jul 17.
9
Fatty acid transport protein 2 reprograms neutrophils in cancer.脂肪酸转运蛋白 2 重编程癌症中的中性粒细胞。
Nature. 2019 May;569(7754):73-78. doi: 10.1038/s41586-019-1118-2. Epub 2019 Apr 17.
10
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma.蛋白质组学鉴定早期肝细胞癌的新治疗靶点。
Nature. 2019 Mar;567(7747):257-261. doi: 10.1038/s41586-019-0987-8. Epub 2019 Feb 27.

中性粒细胞与载脂蛋白A1比值可预测接受经动脉化疗栓塞术的肝细胞癌患者的总生存期。

Neutrophil-to-Apolipoprotein A1 Ratio Predicted Overall Survival in Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.

作者信息

Chen Jie, Chen Yong-Jian, Jiang Nan, Xu Jian-Liang, Liang Zi-Ming, Bai Ming-Jun, Xing Yan-Fang, Liu Zhuo, Wu Xiang-Yuan, Li Xing

机构信息

Department of Medical Oncology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.

Department of Guangdong Key Laboratory of Liver Disease, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.

出版信息

Oncologist. 2021 Aug;26(8):e1434-e1444. doi: 10.1002/onco.13743. Epub 2021 Mar 24.

DOI:10.1002/onco.13743
PMID:33675070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8342583/
Abstract

PURPOSE

The purpose of this study was to investigate the predictive capability of neutrophil-to-apolipoprotein A1 ratio (NAR) for predicting overall survival (OS) among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE).

PATIENTS AND METHODS

We investigated the clinical features of 554 patients with HCC receiving TACE and assessed NAR's predictive value for OS with 222 patients (the discovery cohort) and 332 patients (the validation cohort). The association of NAR with circulation lectin-type oxidized low-density lipoprotein receptor-1-positive (LOX-1 ) polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) was illustrated.

RESULTS

Multivariate Cox regression revealed that lymphocyte count; Tumor, Node, Metastasis (TNM) stage; and NAR were independent prognostic factors in the discovery cohort. The validation cohort confirmed the independent prognostic value of TNM stage and NAR. Patients with low NAR (<2.7) displayed significantly increased OS in the discovery cohort (59.8 months vs. 21 months), the validation group (38.0 months vs. 23.6 months), and the total cohort (44.1 months vs. 22.0 months). A Cox proportional hazards model was used to combine Cancer of the Liver Italian Program (CLIP) score with discretized NAR. C-index illustrated that NAR-integrated CLIP score was the best model compared with NAR and CLIP score. Furthermore, NAR-CLIP presented superior predictive capacity for 10-, 20-, 30-, 40-, 50-, and 60-month survival compared with CLIP score by survival receiver-operator characteristic analysis in the discovery cohort, validation cohort, and total cohort. NAR was significantly associated with LOX-1 PMN-MDSCs by linear regression.

CONCLUSION

This study identified NAR as an independent predictor for OS among patients with HCC receiving TACE. NAR reflected circulation LOX-1 PMN-MDSC level.

IMPLICATIONS FOR PRACTICE

The present study identified neutrophil-to-apolipoprotein A1 ratio (NAR) as an independent predictor for overall survival among patients with hepatocellular carcinoma receiving transarterial chemoembolization. NAR reflected circulation level of lectin-type oxidized low-density lipoprotein receptor-1-positive polymorphonuclear myeloid-derived suppressor cells.

摘要

目的

本研究旨在探讨中性粒细胞与载脂蛋白A1比值(NAR)对接受经动脉化疗栓塞术(TACE)的肝细胞癌(HCC)患者总生存期(OS)的预测能力。

患者与方法

我们调查了554例接受TACE的HCC患者的临床特征,并评估了NAR对222例患者(发现队列)和332例患者(验证队列)OS的预测价值。阐述了NAR与循环凝集素型氧化低密度脂蛋白受体-1阳性(LOX-1)多形核髓源性抑制细胞(PMN-MDSCs)的关联。

结果

多变量Cox回归显示,淋巴细胞计数、肿瘤-淋巴结-转移(TNM)分期和NAR是发现队列中的独立预后因素。验证队列证实了TNM分期和NAR的独立预后价值。低NAR(<2.7)的患者在发现队列(59.8个月对21个月)、验证组(38.0个月对23.6个月)和总队列(44.1个月对22.0个月)中的OS显著延长。使用Cox比例风险模型将意大利肝癌项目(CLIP)评分与离散化的NAR相结合。C指数表明,与NAR和CLIP评分相比,NAR整合CLIP评分是最佳模型。此外,通过生存接受者操作特征分析,在发现队列、验证队列和总队列中,NAR-CLIP在预测10、20、30、40、50和60个月生存率方面比CLIP评分具有更高的预测能力。通过线性回归分析,NAR与LOX-1 PMN-MDSCs显著相关。

结论

本研究确定NAR是接受TACE的HCC患者OS的独立预测指标。NAR反映了循环LOX-1 PMN-MDSC水平。

对实践的启示

本研究确定中性粒细胞与载脂蛋白A1比值(NAR)是接受经动脉化疗栓塞术的肝细胞癌患者总生存期的独立预测指标。NAR反映了凝集素型氧化低密度脂蛋白受体-1阳性多形核髓源性抑制细胞的循环水平。